- WAT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $50.8 million.
- WAT has traded 806,514 shares today.
- WAT traded in a range 234.5% of the normal price range with a price range of $3.95.
- WAT traded below its daily resistance level (quality: 48 days, meaning that the stock is crossing a resistance level set by the last 48 calendar days. The resistance price is defined by the Price - $0.01 at the time of the signal).
Stocks matching the 'Water-Logged and Getting Wetter' criteria are worthwhile stocks to watch for a variety of factors including historical back testing and volatility. Trade-Ideas targets these opportunities because the stock is exhibiting an unusual behavior while displaying negative price action. In this case, the stock crossed an important inflection point; namely, "support" while at the same time the range of the stock's movement in price is twice its normal size. This large range foreshadows a possible continuation as the stock moves lower. EXCLUSIVE OFFER: Get the inside scoop on opportunities in WAT with the Ticky from Trade-Ideas. See the FREE profile for WAT NOW at Trade-Ideas More details on WAT: Waters Corporation operates as an analytical instrument manufacturer in the United States and internationally. WAT has a PE ratio of 25. Currently there are 2 analysts that rate Waters a buy, 1 analyst rates it a sell, and 10 rate it a hold. The average volume for Waters has been 441,500 shares per day over the past 30 days. Waters has a market cap of $11.2 billion and is part of the health care sector and health services industry. The stock has a beta of 0.05 and a short float of 2.8% with 5.43 days to cover. Shares are up 20% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Waters as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Highlights from the ratings report include:
- WAT's revenue growth has slightly outpaced the industry average of 3.0%. Since the same quarter one year prior, revenues slightly increased by 6.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The debt-to-equity ratio is somewhat low, currently at 0.80, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with this, the company maintains a quick ratio of 4.65, which clearly demonstrates the ability to cover short-term cash needs.
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Life Sciences Tools & Services industry and the overall market, WATERS CORP's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
- The gross profit margin for WATERS CORP is rather high; currently it is at 63.26%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 20.86% is above that of the industry average.
- You can view the full Waters Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.